Charles River Laboratories International Inc. (CRL) -0.05

Trade CRL
NOW!
Last Trade:38.18Short Ratio:4.10
Last Trade Time:4:01pmDay Range:37.82 - 38.41
Ask:Year Range:23.29 - 40.14
Bid:One Year Target:40.33
Open:38.35Exchange:NYSE
Volume:378097EBITDA:277.1M
Prev. Close:38.23Market Cap:2.516B
50 Day Moving:37.39Div Yield:
200 day moving:35.7306PE:21.92

Related RealMoney articles from TheStreet.com

Netflix: Analysts' Upgrades, Downgrades

Setback for MannKind - Analyst Blog

Posted on 03/16/10 at 2:17pm
MannKind Corp. (MNKD) suffered a major setback with respect to its lead product, Afrezza, inhaled insulin for treating type I and type II diabetes. The company received a complete response letter (CRL) from the US Food & Drug Administration (FDA) recently.  
Click here to read the rest of the article

Bayer Downgraded to Underperform - Analyst Blog

Posted on 03/15/10 at 11:15am
We have recently downgraded our recommendation on Bayer (BAYRY) to Underperform from Neutral. During the fourth quarter of 2009, the company’s core earnings per share came in at €0.90 surpassing €0.71 reported in the year-ago period. 
Click here to read the rest of the article

Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy

Posted on 03/15/10 at 9:42am
Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy PR Newswire EAST BRUNSWICK, N.J., March 15
Click here to read the rest of the article

Charles River Laboratories: The Trend Continues Up (CRL)

Posted on 03/11/10 at 7:33pm
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE: CRL) on January 07, 2010 at $34.20. In approximately 2 months, Charles River Laboratories has returned 13.9% as of Thursday's closing price of $38.97.
Click here to read the rest of the article

Electricians Are as Intelligent as Merchant Bankers

Posted on 03/09/10 at 5:06am
LONDON, UNITED KINGDOM--(Marketwire - March 9, 2010) - Electricians and care-workers are as intelligent as professors and merchant bankers, claims a new report.
Click here to read the rest of the article

Charles River to Present at Cowen and Raymond James Conferences

Posted on 03/08/10 at 10:03am
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Cowen and Company 30th Annual Health Care Conference in Boston, Massachusetts on Wednesday, March 10th, at 10:15 a.m.
Click here to read the rest of the article

SmarTrend's Trend Spotter See Continued Upward Momentum on Shares of Charles River Laboratories (CRL)

Posted on 03/03/10 at 12:00pm
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE: CRL) on January 07, 2010 at $34.20. In approximately 2 months, Charles River Laboratories has returned 13.9% as of today's recent price of $38.95.
Click here to read the rest of the article

Uptrend Spotted in Shares of Charles River Laboratories (CRL)

Posted on 02/24/10 at 2:35pm
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE: CRL) on January 07, 2010 at $34.20. In approximately 2 months, Charles River Laboratories has returned 9.4% as of today's recent price of $37.42.
Click here to read the rest of the article

Transcept Pharmaceuticals Provides Update on Intermezzo(R) Regulatory Review

Posted on 02/23/10 at 2:51pm
Transcept Pharmaceuticals Provides Update on Intermezzo(R) Regulatory Review PR Newswire POINT RICHMOND, Calif., Feb. 22
Click here to read the rest of the article

J&J Returns Drug Rights - Analyst Blog

Posted on 02/22/10 at 4:39pm
In a major setback for Johnson & Johnson (JNJ), the company has decided to return global rights of ceftobiprole to its Swiss partner, Basilea Pharmaceuticals. The decision was taken following rejection of the marketing application for the drug in Europe.  
Click here to read the rest of the article